Estimation of Public Health Impact with Use of Nirsevimab During the 2024–2025 RSV Season in the USA: a Modeling Study
Abstract Introduction Respiratory syncytial virus (RSV) is a leading cause of medically attended lower respiratory tract disease (MA-LRTD) and hospitalization among infants in the USA. With the introduction in 2023 of nirsevimab, a long-acting monoclonal antibody for infant RSV prevention, early dat...
Збережено в:
| Автори: | , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Adis, Springer Healthcare
2026-02-01
|
| Серія: | Pulmonary Therapy |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1007/s41030-026-00348-z |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|